All surgeries were performed by a single experienced surgeon (S. G.) using a standard phacoemulsification technique under topical anesthesia, using the Centurion Precision system (Alcon Laboratories, Fort Worth, TX, USA). Through a temporal clear corneal incision of 2.8 mm, a 5.0–5.5 mm capsulorhexis was aimed and direct chop technique was used for nuclear deployment. After irrigation and aspiration of the cortex, the left side port was hydrated and BSS injected from the main wound to inflate the bag and form the anterior chamber. In the Tecnis-1 group, the UNFOLDER Platinum 1 Series Screw-Style Inserter (Johnson & Johnson, New Brunswick, NJ, USA) was used to inject the Tecnis-1 IOL through a 2.8-mm temporal clear corneal incision, whereas in the Optiflex Genesis and Eyecryl Plus (ASHFY 600) groups, BES22 and Hydroject R (BHC150C)-1 injectors were used, respectively, for IOL loading and implantation. Intraoperative unfolding time was recorded by an independent observer as the time taken from injection to complete unfolding of both the haptics of the IOL inside the capsular bag. Any device-related intraoperative complication such as haptic or optic breakage, or explantation of the IOL due to device damage or wrong IOL power, was recorded for all the three study groups.
Postoperative topical therapy included topical prednisolone (1%, Pred Forte, Allergan) six times for 6 weeks, tapering weekly, moxifloxacin (0.5%, Vigamox, Alcon) four times for 2 weeks, nepafenac (0.1%, Nevanac, Alcon) three times for 4 weeks, and lubricants four times or SOS for 4 weeks or more.
Follow-up examinations were performed at 1 day, 2 weeks, 3 months, 6 months, and 12 months after surgery. Slit-lamp examination was performed on post-op day 1 to assess the corneal clarity, anterior chamber inflammation, and IOL position. From 1 month onward, in addition to the above, assessment of manifest refraction, uniocular and binocular uncorrected and corrected distance visual acuity (UDVA, CDVA), uniocular and binocular uncorrected and corrected near visual acuity (UNVA, CNVA), photopic contrast sensitivity using CSV-1000 (Vector Vision, Greenville, OH, USA), and defocus curve charting from +3.5 to −3.5 D were evaluated.
Postoperative topical therapy included topical prednisolone (1%, Pred Forte, Allergan) six times for 6 weeks, tapering weekly, moxifloxacin (0.5%, Vigamox, Alcon) four times for 2 weeks, nepafenac (0.1%, Nevanac, Alcon) three times for 4 weeks, and lubricants four times or SOS for 4 weeks or more.
Follow-up examinations were performed at 1 day, 2 weeks, 3 months, 6 months, and 12 months after surgery. Slit-lamp examination was performed on post-op day 1 to assess the corneal clarity, anterior chamber inflammation, and IOL position. From 1 month onward, in addition to the above, assessment of manifest refraction, uniocular and binocular uncorrected and corrected distance visual acuity (UDVA, CDVA), uniocular and binocular uncorrected and corrected near visual acuity (UNVA, CNVA), photopic contrast sensitivity using CSV-1000 (Vector Vision, Greenville, OH, USA), and defocus curve charting from +3.5 to −3.5 D were evaluated.
